CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environment ...
When combined with venetoclax and azacitidine (standard-of-care treatments for AML), STX-0712 improved therapeutic efficacy in 60% of patient samples by differential targeting both CCR2-positive ...
Data demonstrate dose dependent survival advantage with AUTX-703 in primary patient-derived orthotopic AML model ...
Tiprelestat was safe and well tolerated, with initial signs of clinical efficacy ...
WEST CHESTER, PA, USA I 09, 2024 I Molecular Targeting Technologies, Inc. (MTTI) published preclinical study results for their proprietary ...